683 Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

683 Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-350,000	Closed	-$3.36M	–	256
2024 Q4	$3.36M	Buy	+350,000	New	+$1.83M	0.21%	78
2023 Q2	–	Sell	-24,000	Closed	-$73.9K	–	267
2023 Q1	$73.9K	Sell	24,000 -12,966	-35%	-$77.7K	0.01%	234
2022 Q4	$196K	Buy	+36,966	New	+$169K	0.02%	167

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

683 Capital Management's PSTX Position: Q1 2025 in Review

683 Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 350,000 shares — an estimated $3.36M sold.

683 Capital Management first reported a position in PSTX in Q4 2022 and held it in 3 quarters. The position peaked at $3.36M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

683 Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
683 Capital Management sold 350,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.36M.
683 Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
683 Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $3.36M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.